Atlas Trials

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Clinical trial NCT04792502 · RECRUITING

Trial details

NCT number
NCT04792502
Sponsor
Brown University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Follicular LymphomaMarginal Zone LymphomaB-cell Lymphoma
Start date
2022-07-14
Primary completion
2027-08-31
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.